Business
Incannex (ASX:IHL) share price backtracks on FDA update
The Incannex Healthcare Ltd (ASX: IHL) share price is in reverse during late-afternoon trade. This comes despite the company’s positive pre-investigational new drug application (pre-IND) meeting with the United States Food and Drug Administration (FDA).
At the time of writing, the healthcare company’s shares are trading at 28.5 cents, down 1.7%. In comparison, the All Ordinaries Index (ASX: XAO) is 0.4% higher to 7,288 points.
FDA update
According to its release, Incannex announced it received positive feedback from the FDA Pre-IND meeting regarding the regulatory pathway for IHL-675A.
Incannex’s IHL-675A is a novel therapy that comprises hydroxychloroquine (HCQ) and cannabidiol (CBD). The medical therapy is being targeted…
-
Business17 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
General18 hours agoFootballers and movie stars: PM’s Shanghai tourism push
-
Noosa News17 hours agoYIMBYs vs NIMBYs as the battle for affordable housing moves into your backyard
-
General15 hours ago‘Hidden and radical’ power of First Nations women unlocked in big hART’s Punkaliyarra project